ViiV close to licensing out Celsentri in India; rules out compulsory licensing concerns
This article was originally published in Scrip
ViiV Healthcare, the new holder of rights to Celsentri (maraviroc), is in advanced discussions to potentially license out the HIV therapy in India, a move that could perhaps work in its favour against any potential compulsory licensing challenge.
You may also be interested in...
An Indian expert panel has sought data on ViiV Healthcare's HIV entry inhibitor maraviroc (Selzentry/Celsentri) - among the drugs cleared, some years ago, with a trial waiver in the country and recommended for re-examination by a Parliamentary committee.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.